The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
350 Northern Blvd STE 324 - 1079
Albany, NY 12204-1000
(866) 900-7421
Galactosemia Foundation is a non-profit, voluntary health organization dedicated to maximizing the potential for the development of individuals with galactosemia, which is a rare genetic metabolic disorder. Galactosemia is characterized by the inability of the body to break down (metabolize) galactose, which is a normal byproduct of lactose (e.g., milk) metabolism. The affected individual is missing the enzyme that converts galactose to glucose. Serious complications can occur including abnormal enlargement of the liver, kidney failure, cataracts, and/or brain damage. The objectives of the organization are to provide support and educational information to families affected by galactosemia and interested health care professionals; facilitate communication between professionals and families with galactosemia; and support professionals in the research of the treatment of galactosemia. Galactosemia Foundation provides support to parents of affected children; publishes a self-titled periodic newsletter; seeks to stimulate ongoing clinical research; distributes educational materials on galactosemia; operates a parent help line; and distributes appropriate dietary information on the disease.
Please Note
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.
